Oslo, 4 November 2025: Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement and retail offering.

Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced a poster presentation highlighting extended follow up analyses examining ...

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to prevent recurrence and metastasis in cancer patients by targeting and eradicating cancer stem cells through the activation of ...

Initial results of a Phase 1 / 2 open label study of AT-02, the company’s lead pan-amyloid removal therapeutic candidate, in patients with AL amyloidosis will be presented at ASH. The presentation ...

The UAB site joins the list of clinical centers participating in the Company’s global Phase 1/1b trial, which is designed to assess the safety, tolerability, pharmacokinetics (PK), and ...

Cash balance of $344.8 million as of September 30, 2025, together with net proceeds of ~$445 million from October 2025 equity offering, with expected runway into 2028 BEDFORD, Mass., Nov. 04, 2025 ...

Lausanne, Switzerland, November 4, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported ...

EDAP to Present at Jefferies Global Healthcare Conference in London Company to Present and Host 1x1 Investor Meetings on Tuesday, November 18th, 2025 ...

MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its ...

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today is providing a number of strategic updates, including its recently executed option agreement with Incyte ...

Purespring co-author paper with real world evidence on epidemiological prevalence data of NPHS2 pathogenic variants across global populations London – 4 November 2025 – Purespring Therapeutics, a ...

AMT-143 is a long-acting local analgesic for postsurgical pain control. It is administered via instillation at the time of the surgery. In a Phase 1 study, AMT-143 demonstrated sustained release of ...